Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "gSaxenda"

5 News Found

FDA greenlights Biocon’s Liraglutide for chronic weight management
News | February 25, 2026

FDA greenlights Biocon’s Liraglutide for chronic weight management

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management

Biocon launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands
News | December 16, 2025

Biocon launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands

Biocon launches GLP -1, Liraglutide, in UK
News | March 01, 2025

Biocon launches GLP -1, Liraglutide, in UK

The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico
Supply Chain | May 14, 2024

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide
Drug Approval | April 01, 2024

Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide

The company had earlier announced about the approval received from the MHRA for Liraglutide

Latest Stories

Roche inaugurates new research home for the Institute of Human Biology

Japan okays new long-acting eye drug

Bayer wins world-first nod in Japan for low-dose MRI contrast agent

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging